Efficacy of mometasone/indacaterol/glycopyrronium in patients with inadequately controlled asthma with respect to baseline eosinophil count: Post hoc analysis of IRIDIUM study

被引：1

作者：

Kostikas, Konstantinos ^{[1
]}

Maspero, Jorge F. ^{[2
]}

Chapman, Kenneth R. ^{[3
]}

Mezzi, Karen ^{[4
]}

Jaumont, Xavier ^{[4
]}

Lawrence, David ^{[4
]}

van Zyl-Smit, Richard ^{[5
,6
]}

机构：

[1] Univ Ioannina, Resp Med Dept, Elenis Zografou 15, Ioannina 45332, Greece

[2] Fdn CIDEA, Allergy & Resp Res Unit, Buenos Aires, Argentina

[3] Univ Toronto, Dept Med, Div Resp Med, Toronto, ON, Canada

[4] Novartis Pharm AG, Basel, Switzerland

[5] Univ Cape Town, Div Pulmonol, Cape Town, South Africa

[6] Univ Cape Town, UCT Lung Inst, Cape Town, South Africa

来源：

RESPIRATORY MEDICINE | 2023年 / 217卷

关键词：

Eosinophil; Lung function; Exacerbations; Mometasone furoate; Indacaterol acetate; Glycopyrronium bromide; PHENOTYPES; TIOTROPIUM; MOMETASONE;

D O I：

10.1016/j.rmed.2023.107334

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Baseline characteristics could potentially guide asthma treatments. We evaluated whether baseline eosinophil levels affect the efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) in patients with inadequately controlled asthma. Method: In this post hoc analysis of IRIDIUM study, efficacy of high-dose MF/IND/GLY (160/150/50 mu g, oncedaily [o.d.]) versus high-dose MF/IND (320/150 mu g o.d.) and high-dose fluticasone/salmeterol (FLU/SAL [500/50 mu g, twice-daily [b.i.d.]); and efficacy of pooled MF/IND/GLY (160/150/50 mu g and 80/150/50 mu g) versus pooled MF/IND (320/150 mu g and 160/150 mu g) was evaluated in patient subgroups with baseline blood eosinophil count of <300 cells/mu L or >= 300 cells/mu L. Results: Overall, 3065 patients were included. At Week 26, high-dose MF/IND/GLY showed improved trough FEV1 versus high-dose MF/IND (.78mL [<300 cells/mu L];Delta 54mL [>= 300 cells/mu L]) and FLU/SAL (Delta 112mL [<300 cells/mu L];Delta 98mL [>= 300 cells/mu L]). Similarly, pooled MF/IND/GLY also showed improved trough FEV1 versus pooled MF/IND (Delta 75mL [<300 cells/mu L];.68mL [>= 300 cells/mu L]). Over 52 weeks, high-dose MF/IND/GLY reduced the annualized rate of moderate or severe asthma exacerbations by 23% and 10%, severe exacerbations by 31% and 15%, and all exacerbation by 33% and 10% versus high-dose MF/IND for subgroups with <300 cells/mu L and >= 300 cells/mu L, respectively; and by 33% and 41%, 45% and 42%, 42% and 39% versus FLU/SAL, respectively. Similarly, pooled MF/IND/GLY reduced exacerbations by 22% and 8%, 21% and 7%, 27% and 8%, versus pooled MF/IND, for the respective subgroups. Conclusion: MF/IND/GLY showed improvement in lung function and reduction in asthma exacerbations over MF/ IND and FLU/SAL independent of baseline eosinophil levels, indicating that eosinophil levels did not affect the efficacy of MF/IND/GLY in patients with inadequately controlled asthma.

引用

页数：9

共 50 条

[41] Rates of asthma attacks in patients with previously inadequately controlled mild asthma treated in clinical practice with combination drug therapy: An exploratory post-hoc analysis
Dal Negro R.W.
Borderias L.
Zhang Q.
Fan T.
Sazonov V.
Guilera M.
Taylor S.D.
BMC Pulmonary Medicine, 9 (1)
[42] Single Inhaler Extrafine Triple Therapy Vs Indacaterol/Glycopyrronium in COPD Patients Previously Treated with LABA/LAMA: Post-Hoc Analysis of the Tribute Study
Scuri, M.
Singh, D.
Fabbri, L. M.
Valente, I.
Guasconi, A.
Vezzoli, S.
Prunier, H.
Cohuet, G.
Muraro, A.
Petruzzelli, S.
Papi, A.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
[43] COMPARISON OF EFFECT OF INDACATEROL WITH SALMETEROL/FLUTICASONE FIXED DOSE COMBINATION ON COPD EXACERBATIONS BASED ON BASELINE BLOOD EOSINOPHIL COUNTS: POST-HOC ANALYSIS FROM THE INSTEAD STUDY
Goyal, Pankaj
Rossi, Andrea
Bader, Giovanni
Pablo, Altman
RESPIROLOGY, 2015, 20 : 43 - 43
[44] Indacaterol/Glycopyrronium/Mometasone Furoate Improves Lung Function and Reduces Exacerbations Versus Long-Acting β2-Agonist/Inhaled Corticosteroid Standard-of-Care in Patients with Uncontrolled Asthma: The Phase III IRIDIUM Study
Kerstjens, H. A. M.
Maspero, J. F.
Chapman, K. R.
van Zyl-Smit, R.
Kato, M.
Hosoe, M.
Tanase, A.
Lavecchia, C.
Pethe, A.
Shu, X.
D'Andrea, P.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
[45] Effect of once daily (o.d.) mometasone/indacaterol/glycopyrronium (MF/IND/GLY) vs o.d. MF/IND and twice daily (b.i.d.) fluticasone/salmeterol (FLU/SAL) with respect to age, age at asthma-onset and BMI at baseline: Subgroup analysis from IRIDIUM study
Kerstjens, H. A.
Lawrence, D.
Mezzi, K.
Brittain, D.
Jaumont, X.
Chapman, K. R.
EUROPEAN RESPIRATORY JOURNAL, 2022, 60
[46] Prognostic and Predictive Value of Blood Eosinophil Count, Fractional Exhaled Nitric Oxide, and Their Combination in Severe Asthma: A Post Hoc Analysis
Shrimanker, Rahul
Keene, Oliver
Hynes, Gareth
Wenzel, Sally
Yancey, Steven
Pavord, Ian D.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 200 (10) : 1308 - 1312
[47] Efficacy of tezepelumab in patients with severe, uncontrolled asthma, according to baseline blood eosinophil count and allergic status: results from the phase 3 NAVIGATOR study
Menzies-Gow, A.
Corren, J.
Cook, B.
Kmita, K.
Llanos-Ackert, J.
Colice, G.
Ambrose, C. S.
ALLERGY, 2021, 76 : 21 - 22
[48] Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study
Senna, Gianenrico
Aliani, Maria
Altieri, Elena
Bracciale, Pietro
Brussino, Luisa
Caiaffa, Maria Filomena
Cameli, Paolo
Canonica, Giorgio Walter
Caruso, Cristiano
D'Amato, Maria
De Michele, Fausto
Del Giacco, Stefano
Di Marco, Fabiano
Menzella, Francesco
Pelaia, Girolamo
Rogliani, Paola
Romagnoli, Micaela
Schino, Pietro
Schroeder, Jan Walter
Vultaggio, Alessandra
Rizzoli, Sara
Zullo, Alessandro
Boarino, Silvia
Palmisano, Marilena
Rossi, Alessandra
Vitiello, Gianfranco
Centanni, Stefano
JOURNAL OF ASTHMA AND ALLERGY, 2022, 15 : 1593 - 1604
[49] Once-Daily Indacaterol Acetate and Mometasone Furoate Fixed-Dose Combination for Treatment of Inadequately-Controlled Asthma: Long-Term Safety Study in the Japanese Population
Nakamura, Y.
D'Andrea, P.
Tanase, A.
Pethe, A.
Tanaka, Y.
Matsuo, K.
Hosoe, M.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
[50] Free triple combination of glycopyrronium, indacaterol and ICS improves lung function and dyspnoea versus free double combination of indacaterol and ICS in patients with COPD: A post-hoc analysis from the GLOW6 study
Vincken, Walter
Aumann, Joseph
Goya, Pankaj
Altman, Pablo
EUROPEAN RESPIRATORY JOURNAL, 2014, 44

← 1 2 3 4 5 →